These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2227630)

  • 1. 1,25-Dihydroxyvitamin D3 in the treatment of idiopathic thrombocythemia and myelofibrosis.
    Foa P; Maiolo AT; Cortellaro M; Ortolani S; Pogliani E; Deliliers GL; Iurlo A; Zocchi L; Gualdoni A; Polli E
    Haematologica; 1990; 75(3):294-5. PubMed ID: 2227630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Beneficial effect of 1,25-dihydroxyvitamin D3 in the treatment of myelofibrosis].
    Palomera L; García Díez I; Martínez R
    Med Clin (Barc); 1989 Sep; 93(7):265-8. PubMed ID: 2811498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-25 (OH)2 D3 in idiopathic myelofibrosis: a preliminary report.
    Petrini M; Cecconi N; Ambrogi F; Grassi B
    Haematologica; 1987; 72(6):567-9. PubMed ID: 3126118
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.
    Lee J
    Ann Hematol; 2009 Jul; 88(7):699-700. PubMed ID: 19030859
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Is 1,25(OH)2D3 effective in chronic osteomyelofibrosis?].
    Eugster C; Brun del Re GP; Bucher U
    Schweiz Med Wochenschr; 1986 Dec; 116(50):1767-70. PubMed ID: 3798067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The beneficial effect of 1,25-dihydroxycholecalciferol on the excess of blasts and the myelofibrosis in 2 cases of chronic myeloproliferative syndrome].
    Raya Sánchez JM; Hernández Nieto L; Brito Barroso ML; Hernández García MT
    Med Clin (Barc); 1994 Mar; 102(10):380-2. PubMed ID: 8182985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA; Pop VP; Seriakov AP
    Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
    Hasselbalch HC; Bjerrum OW; Jensen BA; Clausen NT; Hansen PB; Birgens H; Therkildsen MH; Ralfkiaer E
    Am J Hematol; 2003 Dec; 74(4):238-42. PubMed ID: 14635203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM; Thiele J
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic conference. Chronic myeloproliferative disease with an increase in platelet count in the differential diagnosis of primary (essential, idiopathic) thrombocythemia (PTH)].
    Zankovich R; Thiele J; Fischer R; Diehl V
    Med Klin (Munich); 1986 Jan; 81(1):31-5. PubMed ID: 3785010
    [No Abstract]   [Full Text] [Related]  

  • 20. 1,25-Dihydroxyvitamin D3 and myelofibrosis.
    McCarthy D; Hibbin J; Matutes E; Daniel P; Catovsky D; Goldman JM
    Lancet; 1984 Jun; 1(8389):1298. PubMed ID: 6145004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.